With new results, Sarepta's 2nd gene therapy holds steady

Sarepta said its gene therapy for a rare genetic disease known as Limb-girdle muscular dystrophy continued to help patients two years after a single treatment, with trial participants sustaining functional gains and producing a protein that protects muscle tissue from damage.